Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems

Journal of Controlled Release

Volumn 147, Issue 3, 2010, Pages 342-349

  Mohanan, Deepa ^a   Slütter, Bram ^b   Henriksen Lacey, Malou ^c   Jiskoot, Wim ^b   Bouwstra, Joke A ^b   Perrie, Yvonne ^c   Kündig, Thomas M ^a   Gander, Bruno ^d   Johansen, Pål ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b LEIDEN UNIVERSITY   (Netherlands)

^c ASTON UNIVERSITY   (United Kingdom)

^d ETH ZURICH   (Switzerland)

Author keywords

Adjuvants; Administration routes; Antibodies; Cytokines; Immune response modifiers; Liposomes; Microspheres; Mouse model; Nanoparticles; Vaccine delivery

Indexed keywords

ADJUVANTS; ADMINISTRATION ROUTES; CYTOKINES; IMMUNE-RESPONSE MODIFIERS; MOUSE MODELS; VACCINE DELIVERY;

ANIMALS; IMMUNOLOGY; LIPOSOMES; MATERIALS PROPERTIES; MICROSPHERES; NANOPARTICLES; PHOSPHOLIPIDS; VACCINES;

ANTIBODIES;

GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; LIPOSOME; N TRIMETHYLCHITOSAN; NANOPARTICLE; OVALBUMIN; POLYGLACTIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CELL STIMULATION; CYTOKINE RELEASE; DRUG DELIVERY SYSTEM; DRUG RELEASE; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SPLEEN CELL; TH1 CELL; ZETA POTENTIAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CELLS, CULTURED; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; DRUG ADMINISTRATION ROUTES; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; IMMUNOGLOBULIN G; INTERFERON-GAMMA; KINETICS; LACTIC ACID; LIPOSOMES; MICE; MICE, INBRED BALB C; NANOPARTICLES; OVALBUMIN; PARTICLE SIZE; POLYGLYCOLIC ACID; SOLUBILITY; SPLEEN; TH1 CELLS; TH2 CELLS; TIME FACTORS; VACCINES;

EID: 78049458472     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.08.012     Document Type: Article

References (42)

1. Hanly W.C., Artwohl J.E., Bennett B.T. Review of Polyclonal antibody production procedures in mammals and poultry. ILAR J. 1995, 37(3):93-118.
2. Gupta R.K., Relyveld E.H., Lindblad E.B., Bizzini B., Ben-Efraim S., Gupta C.K. Adjuvants-a balance between toxicity and adjuvanticity. Vaccine 1993, 11(3):293-306.
3. Gupta R.K., Rost B.E., Relyveld E., Siber G.R. Adjuvant properties of aluminum and calcium compounds. Pharm. Biotechnol. 1995, 6:229-248.
4. Gupta R.K. Aluminum compounds as vaccine adjuvants. Adv. Drug Deliv. Rev. 1998, 32(3):155-172.
5. Johansen P., Men Y., Merkle H.P., Gander B. Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination. Eur. J. Pharm. Biopharm. 2000, 50(1):129-146.
6. O'Hagan D.T., Valiante N.M. Recent advances in the discovery and delivery of vaccine adjuvants. Nat. Rev. Drug Discov. 2003, 2(9):727-735.
7. Storni T., Kundig T.M., Senti G., Johansen P. Immunity in response to particulate antigen-delivery systems. Adv. Drug Deliv. Rev. 2005, 57(3):333-355.
8. P. Johansen, D. Mohanan, J.M. Martinez-Gomez, T.M. Kundig, B. Gander, in press. Lympho-geographical concepts in vaccine delivery. J Control Release, doi:10.1016/j.jconrel.2010.05.019.
9. Tamber H., Johansen P., Merkle H.P., Gander B. Formulation aspects of biodegradable polymeric microspheres for antigen delivery. Adv. Drug Deliv. Rev. 2005, 57(3):357-376.
10. Espuelas S., Roth A., Thumann C., Frisch B., Schuber F. Effect of synthetic lipopeptides formulated in liposomes on the maturation of human dendritic cells. Mol. Immunol. 2005, 42(6):721-729.
11. Manolova V., Flace A., Bauer M., Schwarz K., Saudan P., Bachmann M.F. Nanoparticles target distinct dendritic cell populations according to their size. Eur. J. Immunol. 2008, 38(5):1404-1413.
12. Harding C.V., Song R. Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules. J. Immunol. 1994, 153(11):4925-4933.
13. Kovacsovics-Bankowski M., Clark K., Benacerraf B., Rock K.L. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc. Natl Acad. Sci. USA 1993, 90(11):4942-4946.
14. Vidard L., Kovacsovics-Bankowski M., Kraeft S.K., Chen L.B., Benacerraf B., Rock K.L. Analysis of MHC class II presentation of particulate antigens of B lymphocytes. J. Immunol. 1996, 156(8):2809-2818.
15. Cubas R., Zhang S., Kwon S., Sevick-Muraca E.M., Li M., Chen C., Yao Q. Virus-like particle (VLP) lymphatic trafficking and immune response generation after immunization by different routes. J. Immunother. 2009, 32(2):118-128.
16. Heinzerling L., Basch V., Maloy K., Johansen P., Senti G., Wuthrich B., Storni T., Kundig T.M. Critical role for DNA vaccination frequency in induction of antigen-specific cytotoxic responses. Vaccine 2006, 24(9):1389-1394.
17. Johansen P., Storni T., Rettig L., Qiu Z., Der-Sarkissian A., Smith K.A., Manolova V., Lang K.S., Senti G., Mullhaupt B., Gerlach T., Speck R.F., Bot A., Kundig T.M. Antigen kinetics determines immune reactivity. Proc. Natl Acad. Sci. USA 2008, 105(13):5189-5194.
18. Brown D.M., Kamperschroer C., Dilzer A.M., Roberts D.M., Swain S.L. IL-2 and antigen dose differentially regulate perforin- and FasL-mediated cytolytic activity in antigen specific CD4+ T cells. Cell. Immunol. 2009, 257(1-2):69-79.
19. Saraiva M., Christensen J.R., Veldhoen M., Murphy T.L., Murphy K.M., O'Garra A. Interleukin-10 production by Th1 cells requires interleukin-12-induced STAT4 transcription factor and ERK MAP kinase activation by high antigen dose. Immunity 2009, 31(2):209-219.
20. Demento S.L., Eisenbarth S.C., Foellmer H.G., Platt C., Caplan M.J., Mark Saltzman W., Mellman I., Ledizet M., Fikrig E., Flavell R.A., Fahmy T.M. Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy. Vaccine 2009, 27(23):3013-3021.
21. Martinez Gomez J.M., Fischer S., Csaba N., Kundig T.M., Merkle H.P., Gander B., Johansen P. A protective allergy vaccine based on CpG- and protamine-containing PLGA microparticles. Pharm. Res. 2007, 24(10):1927-1935.
22. Henriksen-Lacey M., Bramwell V.W., Christensen D., Agger E.M., Andersen P., Perrie Y. Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen. J. Control. Release 2010, 142(2):180-186.
23. Henriksen-Lacey M., Bramwell V., Perrie Y. Radiolabelling of antigen and liposomes for vaccine biodistribution studies. Pharmaceutics 2010, 2(2):91-104.
24. Hagenaars N., Mastrobattista E., Verheul R.J., Mooren I., Glansbeek H.L., Heldens J.G., van den Bosch H., Jiskoot W. Physicochemical and immunological characterization of N,N,N-trimethyl chitosan-coated whole inactivated influenza virus vaccine for intranasal administration. Pharm. Res. 2009, 26(6):1353-1364.
25. Slutter B., Soema P.C., Ding Z., Verheul R., Hennink W., Jiskoot W. Conjugation of ovalbumin to trimethyl chitosan improves immunogenicity of the antigen. J. Control. Release 2010, 143(2):207-214.
26. Slutter B., Plapied L., Fievez V., Sande M.A., des Rieux A., Schneider Y.J., Van Riet E., Jiskoot W., Preat V. Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination. J. Control. Release 2009, 138(2):113-121.
27. Johansen P., Men Y., Audran R., Corradin G., Merkle H.P., Gander B. Improving stability and release kinetics of microencapsulated tetanus toxoid by co-encapsulation of additives. Pharm. Res. 1998, 15(7):1103-1110.
28. Johansen P., Senti G., Martinez Gomez J.M., Wuthrich B., Bot A., Kundig T.M. Heat denaturation, a simple method to improve the immunotherapeutic potential of allergens. Eur. J. Immunol. 2005, 35(12):3591-3598.
29. Tan M.L., Choong P.F., Dass C.R. Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug delivery. Peptides 2010, 31(1):184-193.
30. O'Hagan D.T., Singh M. Microparticles as vaccine adjuvants and delivery systems. Expert Rev. Vaccin. 2003, 2(2):269-283.
31. Martinez-Gomez J.M., Johansen P., Erdmann I., Senti G., Crameri R., Kundig T.M. Intralymphatic injections as a new administration route for allergen-specific immunotherapy. Int. Arch. Allergy Immunol. 2009, 150(1):59-65.
32. Johansen P., Haffner A.C., Koch F., Zepter K., Erdmann I., Maloy K., Simard J.J., Storni T., Senti G., Bot A., Wuthrich B., Kundig T.M. Direct intralymphatic injection of peptide vaccines enhances immunogenicity. Eur. J. Immunol. 2005, 35(2):568-574.
33. Maloy K.J., Erdmann I., Basch V., Sierro S., Kramps T.A., Zinkernagel R.M., Oehen S., Kundig T.M. Intralymphatic immunization enhances DNA vaccination. Proc. Natl Acad. Sci. USA 2001, 98(6):3299-3303.
34. Senti G., Prinz Vavricka B.M., Erdmann I., Diaz M.I., Markus R., McCormack S.J., Simard J.J., Wuthrich B., Crameri R., Graf N., Johansen P., Kundig T.M. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc. Natl Acad. Sci. USA 2008, 105(46):17908-17912.
35. Mailliard R.B., Son Y.I., Redlinger R., Coates P.T., Giermasz A., Morel P.A., Storkus W.J., Kalinski P. Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J. Immunol. 2003, 171(5):2366-2373.
36. Hosken N.A., Shibuya K., Heath A.W., Murphy K.M., O'Garra A. The effect of antigen dose on CD4+ T helper cell phenotype development in a T cell receptor-alpha beta-transgenic model. J. Exp. Med. 1995, 182(5):1579-1584.
37. Jankovic D., Liu Z., Gause W.C. Th1- and Th2-cell commitment during infectious disease: asymmetry in divergent pathways. Trends Immunol. 2001, 22(8):450-457.
38. Stavnezer J., Guikema J.E., Schrader C.E. Mechanism and regulation of class switch recombination. Annu. Rev. Immunol. 2008, 26:261-292.
39. Senti G., Johansen P., Kundig T.M. Intralymphatic immunotherapy. Curr. Opin. Allergy Clin. Immunol. 2009, 9(6):537-543.
40. Kunzi V., Klap J.M., Seiberling M.K., Herzog C., Hartmann K., Kursteiner O., Kompier R., Grimaldi R., Goudsmit J. Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration. Vaccine 2009, 27(27):3561-3567.
41. Kawase A., Isaji K., Yamaoka A., Kobayashi N., Nishikawa M., Takakura Y. Enhanced antigen-specific antibody production following polyplex-based DNA vaccination via the intradermal route in mice. Vaccine 2006, 24(27-28):5535-5545.
42. Azzi L., El-Alfy M., Martel C., Labrie F. Gender differences in mouse skin morphology and specific effects of sex steroids and dehydroepiandrosterone. J. Invest. Dermatol. 2005, 124(1):22-27.